• Member Atout Capital
  • Sector Life Sciences
  • Date completed 30.09.2022
  • Country Luxembourg
  • Country -

ATOUT CAPITAL advised the shareholders of ABL DIAGNOSTICS in the context of an RTO (Reverse Take-Over) merger using the listed structure ABL DIAGNOSTICS, formerly known as ETABLISSEMENTS FAUVET-GIREL.

This merger of ABL FRANCE into ABL DIAGNOSTICS was approved by the AMF on July 12, 2022 and approved by the shareholders at the General Meeting held on August 3, 2022.

With a valuation of approximately €28 million retained for ABL FRANCE, this activity of development and marketing of diagnostic kits is now housed in the structure ABL DIAGNOSTICS whose shares are admitted to trading on compartment C of Euronext Paris (ISIN FR001400AHX6 – Mnémo ABLD) and could soon call on the market to finance the acceleration of its development.

Atout Capital

Get Started

Find out how the Globalscope family can help you realise your business dreams.